1. Pyeritz RE.Recent progress in understanding the natural and clinical histories of the Marfan syndrome. Trends Cardiovasc Med. 2016 Jul;26(5):423-8.
2. Carrel T, Beyeler L, Schnyder A, et al. Reoperations and late adverse outcome in Marfan patients following cardiovascular surgery. Eur J Cariothorac Surg 2004; 25: 671-5.
3. Murphy-Ryan M, Psychogios A, Lindor NM. Hereditary disorders of connective tissue: A guide to the emerging differential diagnosis. Genet Med 2010; 12(6): 344-54.
4. Erbel R, Aboyans V, Boileau C, et al. 2014 ESC Guidelines on the diagnosis and treatment of aortic diseases Eur Heart Jour 2014; Nov1; 35(41): 2873-926.
5. Loeys BL, Dietz HC, Braverman AC et al. The revised Ghent nosology for the Marfan syndrome; J Med Genet; 2010; 47: 476-85.
6. Ackerman MJ, Priori SG, Willems S, et al. HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Heart Rhythm; 2011; Aug;8(8): 1308-39.
7. Inácio A, Silva AL, Pinto J, et al. Nonsense mutations in close proximity to the initiation codon fail to trigger full nonsense-mediated mRNA decay. J Biol Chem. 2004 Jul 30; 279(31): 32170-80.
8. Faivre L, Collod-Beroud G, Callewaert B, et al. Clinical and mutation-type analysis from an international series of 198 probands with a pathogenic FBN1 exons 24-32 mutation; Eur J Hum Genet; 2009; 17; 491-501.
9. Olivieri J, Smaldone S, Ramirez F. Fibrillin assemblies: extracellular determinants of tissue formation and fibrosis. Fibrogenesis & Tissue Repair. 2010; 3-24.
10. Marfan Universal Database — www.umd.be (15/10/2016).
11. Jensen SA, Aspinall G, Handford PA. C-terminal propeptide is required for fibrillin-1 secretion and blocks premature assembly through linkage to domains cbEGF41-43. PNAS July 15, 2014; 111, 28:10155-60.
12. Bernhardt AMJ, Treede H, Rybczynski M, et al. David-operation vs. Bentall-procedure in patients with Marfan syndrome Thorac cardiovasc Surg 2010; 58-V104.
13. Kirschner R, Hubmacher D, Iyengar G, et al. Classical and Neonatal Marfan Syndrome Mutations in Fibrillin-1 Cause Differential Protease Susceptibilities and Protein Function; The Journal of biological chemistry, 2011; 286, 37; 1; 32810-23.
14. Lacro RV, Dietz HC, Sleeper LA, et al. Atenolol versus losartan in children and young adults with Marfan’s syndrome. N Engl J Med 2014; 371: 2061-71.
